About > Leadership
Laszlo Radvanyi, PhD
Laszlo Radvanyi,  PhD
Laszlo Radvanyi, PhD
President and Scientific Director


Telephone: 416-555-12345

Mobile: 416-555-12345

President and Scientific Director
Dr. Laszlo Radvanyi has extensive cancer research experience in academia as well as in the pharmaceutical industry both in Canada and in the U.S.

After completing his PhD in Clinical Biochemistry and Immunology at the University of Toronto, Dr. Radvanyi was granted a Cancer Research Institute Postdoctoral Fellowship at Harvard Medical School in Boston, MA. He then joined Sanofi Pasteur as a Senior Scientist, where he co-led a cancer vaccine antigen discovery and validation team for five years.

Dr. Radvanyi then relocated to Texas where, for ten years, he was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Centre. While at MD Anderson, he established a GMP-grade T-cell therapy manufacturing program for metastatic melanoma using expanded tumour-infiltrating lymphocytes (TIL) and performed basic research on TIL biology and effector function for which he received an MD Anderson Division of Cancer Medicine Research Award.

Prior to joining OICR, Dr. Radvanyi was the Senior Vice President and Global Head of the Immuno-Oncology Translational Innovation Platform at EMD Serono (Merck KGaA, Darmstadt, Germany). He also served as a Senior Scientific Advisor for EMD Serono, specializing in immunology and immuno-oncology.
While at EMD Serono, Dr. Radvanyi rebuilt and re-organized EMD Serono’s immuno-oncology research platform and rejuvenated their immuno-oncology research pipeline. He recruited key talent and established influential partnerships with academia that focused on biomarker-driven clinical trials. Notably, Dr. Radvanyi established an alliance between EMD Serono and Pfizer for the development of anti-PD-L1 (avelumab) and co-led EMD Serono’s CAR T-cell program in partnership with Intrexon and Ziopharm.

Dr. Radvanyi also has experience in biotech drug discovery and development (founding CSO for Iovance Therapeutics). Iovance is the first company to develop a commercial process for the manufacturing of TIL and TIL therapy for cancer patients making this a reality after decades of academic research. He was a past Associate Editor for the Journal of Immunotherapy for Cancer (JITC), currently serves on the Keystone Conferences Scientific Advisory Board, and serves on grant review panels for numerous national and international agencies. Dr. Radvanyi also serves as on advisory boards for numerous biotechnology companies in the oncology field.

Visit Dr. Bradly G. Wouters' Researcher Page

Dr. Brad Wouters’ lab has identified new signalling pathways that influence how tumours respond to environments with reduced oxygenation. Unlike most tissue, tumour cells can survive and thrive in environments starved of oxygen. Characterized by extreme differences in nutrient supply, pH, and oxygenation, these environments promote tumour malignancy and prevent effective treatment for patients. Using high-throughput approaches the lab is defining the molecular basis of these signalling pathways and establishing their importance for future cancer therapies.